证券日报网讯2月4日，昆药集团（600422）在互动平台回答投资者提问时表示，根据法律法规及监管要 求，公司的经营业绩情况将在法定披露渠道依法依规予以披露，敬请关注公司公告。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 华润三九医药股份有限公司（以下简称"公司"或"华润三九"）董事会2026年第二次会议于2026年2月2日 下午在华润三九医药工业园综合办公中心107会议室召开。会议通知以书面方式于2026年1月30日发出。 会议由公司董事长邱华伟先生主持，本次会议应到董事11人，实到董事11人，公司部分高级管理人员列 席会议。本次会议的召开及程序符合《公司法》和《公司章程》的规定，会议合法有效。会议以投票方 式审议通过了以下议案，并形成决议： 颜炜先生：男，1971年10月出生，中共党员，项目管理学硕士学位，研究生学历。曾任华润三九医药股 份有限公司OTC事业部总经理、康复慢病事业部总经理、首席营销官，昆药集团股份有限公司总裁。现 任华润三九医药股份有限公司副总裁、昆药集团股份有限公司副董事长。 股票代码：000999 股票简称：华润三九 编号：2026一002 华润三九医药股份有限公司 董事会2026年第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、关于聘任公司高级管理人员的议案 本议案提交董事会前已 ...

债 券 周 相关研究 证券分析师 黄伟平 A0230524110002 huangwp@swsresearch.com 王明路 A0230525060003 wangml@swsresearch.com 徐亚 A0230524060002 xuya@swsresearch.com 联系人 徐亚 A0230524060002 xuya@swsresearch.com 2026 年 01 月 31 日 高估值下转债抗回撤能力有限 ——转债周度跟踪 20260130 ⚫ 1. 周观点及展望 ⚫ 本周贵金属高位调整带动权益和转债市场明显回撤，高平价偏股转债估值环比下行幅度 较大，估值高位下转债抗风险能力较差。当前可转债市场定位已呈现四个关键特征：一是 从左侧思维转向右侧交易，不宜过早坚守；二是从配置价值转向交易价值，需警惕机构防 御性抛售带来的下行风险；三是从追求确定性收益转向衡量风险与回报比，短期冲高后应 再次评估其投资价值；四是从债性或衍生品定价转向机构行为与权益预期驱动，交易盘节 前止盈压力可能较大。因此，短期内应当积极防御、守住盈利，为节后低位布局做好准备。 结构方面，从关注高价、次新、不强赎的品种，转向配置 ...

Group 1 - The company, Kunming Pharmaceutical Group, stated that it strictly adheres to laws, regulations, and regulatory requirements, and will fulfill information disclosure obligations in a timely manner if any matters meet the disclosure standards [2] - The stock price fluctuations of the listed company are influenced by multiple factors, including macroeconomic conditions, industry cycles, and market sentiment [2]

证券日报网讯 1月27日，昆药集团在互动平台回答投资者提问时表示，昆药集团财务共享中心成立于 2021年，整体运行成熟、稳定。 （文章来源：证券日报） ...

Core Viewpoint - In 2026, Henan Province aims to deepen reforms in key areas, with a focus on economic growth and structural adjustments in various sectors [2][3][14]. Economic Goals - The main expected targets for 2026 include an economic growth rate of around 5%, industrial added value growth of approximately 6.5%, fixed asset investment growth of about 5%, and retail sales growth of 5.5% [2][13]. - The province aims for a grain production of over 1.3 trillion jin, with a goal to achieve more growth compared to the previous year [2][13]. Reform Initiatives - A new round of state-owned enterprise reform will be initiated, focusing on strategic restructuring and professional integration [3][14]. - The government plans to enhance the investment in strategic emerging industries and the livelihood sector [3][14]. - There will be a comprehensive implementation of zero-based budgeting reforms and performance management mechanisms [3][14]. Employment and Social Policies - The urban unemployment rate is targeted to be around 5.5%, with over 1.1 million new urban jobs expected to be created [2][13]. - The government will implement policies to ensure the synchronization of resident income growth with economic growth [2][13]. Infrastructure and Investment Projects - Over 1,000 key provincial projects will be implemented, with an annual investment completion target of 1 trillion yuan [19]. - Major infrastructure projects include high-speed rail developments and enhancements in digital infrastructure [19][22]. Financial Strategies - The province plans to issue 132.7 billion yuan in local government special bonds to support project construction [8][18]. - There will be an increase in social financing scale by 1 trillion yuan, alongside efforts to manage local government financing platforms effectively [22]. Industry Development - The share of strategic emerging industries in industrial added value is expected to exceed 25% [8][18]. - The government will support the development of six major industrial clusters and 18 rural prosperity industrial chains [22].

1. Report Industry Investment Rating No information provided in the report. 2. Core Viewpoints of the Report - Recently, small and micro-cap stocks have been active. Despite policy cooling signals, they still benefit from loose liquidity. The CSI 2000 and Wind Small and Micro-cap Index have led the gains, which is suitable for the convertible bond style. The underlying stocks of convertible bonds have risen significantly, and the convertible bonds have simultaneously increased in valuation. Valuation indicators such as the convertible bond's 100-yuan premium rate and median price have reached new highs since 2017. Structurally, the price ranges of 130 - 140 yuan and above 150 yuan have shown strong performance. High-parity convertible bonds remain active, while newly issued convertible bonds have relatively poor performance. Currently, the bull market expectation in the equity market is relatively consistent, with high capital activity. Convertible bonds are experiencing a "double hit" market of parity and valuation. However, in the state of strong equity characteristics and high conversion premium rates, it is still necessary to beware of the forced redemption risk of individual bonds [1][2]. 3. Summary by Relevant Catalogs 3.1 Weekly Viewpoint and Outlook - Small and micro-cap stocks are active, and convertible bonds are in a "double hit" market of parity and valuation. However, the forced redemption risk of individual bonds needs to be watched out for [1][2]. 3.2 Convertible Bond Valuation - This week, the underlying stocks of convertible bonds performed actively, and the convertible bonds rose synchronously. The 100-yuan premium rate increased by 0.9% to 33.5%, reaching the 100th percentile since 2017. Currently, the 100-yuan premium rate of convertible bonds is still above the 2 - standard deviation [3]. - The valuations of convertible bonds in each parity range have increased significantly. The valuation increase in the equity - biased area is slightly higher than that in the debt - biased area, but the overall gap has narrowed compared with the previous period. The valuation in the 120 - 140 yuan parity range has increased significantly, mainly due to the significant increase in the activity of the underlying stocks. The valuation in the parity range above 140 yuan has only increased slightly, mainly due to the disturbance of forced redemption [7]. - From the perspective of individual bonds, in the high - parity area, Xinfu and Yinbang have entered the forced redemption process, and the expectation of forced redemption has increased, resulting in a relatively large decline in the conversion premium rate. Shuangliang, Hebang, Ruike, Zhoubang, Hengshuai, and Daimei have significantly increased their valuations due to the obvious rise of their underlying stocks. The valuations in the balanced and debt - biased areas have generally increased slightly. The valuations of near - maturity convertible bonds are weak. In addition, the valuation of the newly issued Anke convertible bond is slowly shrinking due to the weak performance of its underlying stock [8]. 3.3 Clause Tracking 3.3.1 Redemption - This week, Tianjian, Fuli, Sailong, Shentong, Beigang, and Huazheng convertible bonds announced redemptions, and 2 convertible bonds announced non - redemptions, with a forced redemption rate of 75%. Currently, there are 49 convertible bonds in the redemption process. Next week, 8 are expected to meet the redemption conditions, and 10 are expected to issue announcements of potential redemption triggers. In addition, 26 convertible bonds are expected to enter the forced redemption counting period within the next month [1][17][19]. 3.3.2 Downward Revision - This week, Hongchuan convertible bond proposed a downward revision, and Fangyuan convertible bond announced the downward revision result (not revised to the bottom). As of now, 101 convertible bonds are in the temporary non - downward revision range, 20 convertible bonds cannot be downward - revised due to net asset constraints, 1 convertible bond has triggered the condition and the stock price is still lower than the downward - revision trigger price but no announcement has been made, 16 convertible bonds are accumulating downward - revision days, and 3 convertible bonds have issued downward - revision board plans but have not yet gone to the general meeting of shareholders [1][23]. 3.3.3 Put Option - This week, no convertible bonds issued conditional put option announcements. As of now, 3 convertible bonds are accumulating put option trigger days, among which 1 convertible bond proposed a downward revision, and 2 convertible bonds are in the temporary non - downward revision range [1][27]. 3.4 Primary Issuance - As of now, there are 10 convertible bonds in the process of consent registration, with a to - be - issued scale of 8.8 billion yuan, and no convertible bonds are in the process of passing the listing committee [29].

2019年-2025年全国医药制造业出口货值统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：国药现代（600420），昆药集团（600422），片仔癀（600436），千金药业（600479），津 药药业（600488），国药股份（600511），联环药业（600513），合富中国（603122），康惠制药 （603139），莎普爱思（603168），奥翔药业（603229），大参林（603233） 相关报告：智研咨询发布的《2026-2032年中国医药制造外包（CMO/CDMO）行业市场发展态势及未来 趋势研判报告》 根据国家统计局数据可知：2025年12月全国医药制造业出口货值为225.6亿元，同比下降3.5%；2025年 全国医药制造业累计出口货值为2367.2亿元，累计同比增长9.9%。 ...

Group 1 - The retail industry is shifting towards consumer-centric approaches, focusing on brand and academic integration, driven by aging population demands for health solutions [2] - The "14th Five-Year Plan" strategy is structured around a "one body, two wings" framework, with each of the three listed companies focusing on different core areas: consumer health, prescription drugs, and silver-haired health [3] - The company aims to drive growth through both internal and external strategies, focusing on management, brand, and product line synergies while pursuing acquisitions in key areas [4] Group 2 - The CHC business has surpassed 10 billion in revenue during the "14th Five-Year Plan," with significant achievements in market expansion and brand development [5] - The sales expense ratio is expected to remain stable, with the prescription drug business benefiting from collaborative synergies post-acquisition [6][7] - The company is currently in a strategic adjustment phase, focusing on channel restructuring and brand building to reduce reliance on prescription drugs [8]

Group 1: Industry Outlook - The retail industry is expected to focus on consumer-centric approaches, returning to brand and academic fields, with a long-term growth trend driven by industry innovation [2][3] - The integration of online and offline services will shape the competitive landscape for the next five years, with an increasing demand for health solutions driven by an aging population [3] Group 2: Strategic Planning - The "14th Five-Year" plan is currently in progress, with three major companies focusing on core business areas: CHC for China Resources Sanjiu, prescription drugs for Tianshili, and traditional Chinese medicine for Kunming Pharmaceutical [4] - The strategic framework is "one core and two wings," aiming for leadership in the pharmaceutical industry through collaboration and mutual empowerment among the three companies [4][5] Group 3: Mergers and Acquisitions - Future acquisitions will focus on both "in-depth" and "external" growth strategies, with an emphasis on consumer health, medical health, and silver health sectors [5] - The company will seek potential brand assets in the CHC sector and explore innovative opportunities in prescription drugs [5] Group 4: Innovation and Product Development - The company has established partnerships for innovative projects, particularly in cardiovascular diseases, with a focus on heart failure treatments [6][7] - The company aims to expand its product pipeline in chronic diseases, especially diabetes, and will adopt diverse methods to acquire new products [7] Group 5: Sales and Financial Performance - The sales model is divided into CHC (retail) and prescription drugs (hospital), with sales expense rates influenced by seasonal factors [8] - The company anticipates stable sales expense rates in the long term, with a projected revenue growth exceeding the industry average, aiming for double-digit growth [9][10] Group 6: Product Progress and Market Position - The 999 Yiqi Qingfei Granules, developed in collaboration with academic experts, fills a market gap for respiratory infection recovery medications and has been included in the National Medical Insurance Directory [11] - The prescription drug business is expected to improve, leveraging synergies with Tianshili to enhance management and operational efficiency [12] Group 7: CHC Business Development - The CHC business has surpassed 10 billion RMB during the "14th Five-Year" period, focusing on brand and product expansion [13][14] - The company aims to maintain market leadership in various health sectors by adapting to consumer needs and optimizing brand strategies [14]